Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Novo Training Its Sights on Oral Diabetes Market with Rybelsus, Not Switches from GLP-1 Injectables
Novo Nordisk Pharma is looking to pit its recently launched oral GLP-1 agent Rybelsus (semaglutide) against oral rivals like DPP-4 and SGLT2 inhibitors, rather than injectables in the same class, by pitching its strong efficacy in reducing HbA1c. On February…
To read the full story
Related Article
- 1st Oral GLP Agent Hits Japan Shelves
February 8, 2021
- 4 Drug Makers Flag GLP-1 Use for “Weight Loss” after Diabetes Society Warning
August 24, 2020
- Novo Joins Hands with MSD in Oral Semaglutide Promotion
December 10, 2019
BUSINESS
- Ono, AstraZeneca to End Japan Co-Promotion of Forxiga
March 2, 2026
- Enhertu Filed in Japan as Adjuvant Therapy for Early Breast Cancer
March 2, 2026
- Shionogi, Torii File Lotion Form of Corectim in Japan
March 2, 2026
- Arcalis Completes mRNA Drug Facility, Establishes End-to-End CDMO Platform
March 2, 2026
- GSK Files Hep B Drug in Japan as First Global Submission
February 27, 2026
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…